John Nuss, the Chief Scientific Officer of Ventyx Biosciences, Inc. (NASDAQ:VTYX), just lately offered shares of the corporate’s frequent inventory. In line with a latest submitting with the Securities and Alternate Fee, Nuss offered 13,161 shares on December 19, 2024, at a median worth of $2.2553 per share, totaling roughly $29,682. The transaction occurred close to the inventory’s 52-week low of $1.67, with shares presently buying and selling at $2.28. InvestingPro evaluation signifies the inventory is presently undervalued, with analysts setting worth targets starting from $2 to $21.
This transaction was carried out as a broker-assisted sale to cowl tax obligations associated to the vesting of restricted inventory models. Following this sale, Nuss holds 485,701 shares of Ventyx Biosciences.
Moreover, on December 17, 2024, Nuss acquired 34,930 shares of frequent inventory via the vesting of restricted inventory models, with no money exchanged on this transaction.
In different latest information, Ventyx Biosciences has introduced a number of key developments. The corporate offered encouraging long-term efficacy information from its Section 2 research of tamuzimod, a remedy for ulcerative colitis, on the United European Gastroenterology Week Convention. The research achieved its main endpoint of medical remission, with elevated remission charges noticed for each 30 mg and 60 mg doses. Regardless of these constructive outcomes, Ventyx Biosciences doesn’t plan to advance tamuzimod into Section 3 trials with no associate.
As well as, the corporate has acquired a $27 million funding from pharmaceutical large Sanofi (NASDAQ:), linked to Ventyx’s drug candidate for Parkinson’s illness and weight problems, VTX3232. This funding is predicted to increase the corporate’s monetary runway into the second half of 2026. Nevertheless, the corporate’s Section 2 trial of one other drug, VTX958, didn’t meet its main aim in treating Crohn’s illness, and Ventyx has indicated it won’t conduct additional trials of VTX958 with its inner sources.
Analysts at H.C. Wainwright have maintained a Impartial score for Ventyx Biosciences, whereas Piper Sandler has stored its Obese score and Oppenheimer has retained an Outperform score regardless of a lowered worth goal. Lastly, Ventyx Biosciences reported a web quarterly lack of $38.6 million, with money, money equivalents, and marketable securities totaling $279.7 million.
This text was generated with the help of AI and reviewed by an editor. For extra data see our T&C.
